- Home
- INCY
INCY
Incyte Corp.
as 11-22-2024 4:00pm EST
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | N/A | IPO Year: | 1993 |
| Target Price: | $75.47 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -92.12 |
| 52 Week Low/High: | $50.35 - $83.95 | Next Earning Date: | 10-29-2024 |
| Revenue: | $4,075,860,000 | Revenue Growth: | 12.94% |
| Revenue Growth (this year): | 16.03% | Revenue Growth (next year): | 10.35% |
Stock Insider Trading Activity of Incyte Corp. (INCY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flannelly Barry P | INCY | EVP & General Manager US | Nov 6 '24 | Sell | $80.10 | 3,680 | $293,209.76 | 60,298 | |
| Tray Thomas | INCY | Principal Accounting Officer | Sep 12 '24 | Sell | $63.16 | 954 | $60,209.02 | 24,825 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock
Zacks
2 days ago
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Morningstar Research
3 days ago
Analyst Report: Incyte Corporation
MT Newswires
4 days ago
Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
MT Newswires
4 days ago
Equity Markets Close Mixed Ahead of Nvidia Earnings
Investopedia
4 days ago
S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
MT Newswires
4 days ago
Sector Update: Health Care Stocks Decline
MT Newswires
4 days ago
Top Midday Decliners
Compare INCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.